American Capital Management Inc. increased its holdings in shares of Medidata Solutions Inc (NASDAQ:MDSO) by 3.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 669,649 shares of the company’s stock after purchasing an additional 21,136 shares during the period. Medidata Solutions makes up about 2.1% of American Capital Management Inc.’s holdings, making the stock its 19th biggest position. American Capital Management Inc. owned 1.12% of Medidata Solutions worth $49,092,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Dimensional Fund Advisors LP grew its stake in Medidata Solutions by 0.5% during the first quarter. Dimensional Fund Advisors LP now owns 130,588 shares of the company’s stock worth $8,202,000 after purchasing an additional 663 shares during the period. Oregon Public Employees Retirement Fund grew its stake in Medidata Solutions by 3.0% during the second quarter. Oregon Public Employees Retirement Fund now owns 22,786 shares of the company’s stock worth $1,836,000 after purchasing an additional 666 shares during the period. Front Row Advisors LLC grew its stake in Medidata Solutions by 6.1% during the second quarter. Front Row Advisors LLC now owns 12,623 shares of the company’s stock worth $980,000 after purchasing an additional 725 shares during the period. Polen Capital Management LLC grew its stake in Medidata Solutions by 12.2% during the second quarter. Polen Capital Management LLC now owns 7,413 shares of the company’s stock worth $597,000 after purchasing an additional 806 shares during the period. Finally, Metropolitan Life Insurance Co. NY grew its stake in Medidata Solutions by 3.0% during the second quarter. Metropolitan Life Insurance Co. NY now owns 34,464 shares of the company’s stock worth $2,776,000 after purchasing an additional 993 shares during the period.
In other Medidata Solutions news, EVP Michael I. Otner sold 7,030 shares of the firm’s stock in a transaction that occurred on Tuesday, October 23rd. The stock was sold at an average price of $69.40, for a total value of $487,882.00. Following the completion of the sale, the executive vice president now owns 62,548 shares of the company’s stock, valued at $4,340,831.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 4.70% of the company’s stock.
Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings data on Thursday, October 18th. The company reported $0.42 EPS for the quarter, beating the Zacks’ consensus estimate of $0.36 by $0.06. Medidata Solutions had a return on equity of 10.70% and a net margin of 8.43%. The firm had revenue of $163.41 million during the quarter, compared to analysts’ expectations of $162.09 million. During the same quarter last year, the firm posted $0.33 earnings per share. The company’s revenue for the quarter was up 17.6% compared to the same quarter last year. As a group, research analysts predict that Medidata Solutions Inc will post 0.85 EPS for the current year.
Several equities research analysts recently commented on the company. ValuEngine raised Medidata Solutions from a “hold” rating to a “buy” rating in a research note on Thursday. JPMorgan Chase & Co. decreased their target price on Medidata Solutions to $74.00 and set a “neutral” rating for the company in a research note on Friday, October 19th. Royal Bank of Canada set a $86.00 target price on Medidata Solutions and gave the stock a “buy” rating in a research note on Friday, October 19th. Piper Jaffray Companies decreased their target price on Medidata Solutions from $96.00 to $93.00 in a research note on Thursday, October 18th. Finally, Zacks Investment Research cut Medidata Solutions from a “hold” rating to a “sell” rating in a research note on Tuesday, October 16th. One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the stock. Medidata Solutions currently has an average rating of “Buy” and a consensus target price of $84.64.
About Medidata Solutions
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.
Featured Story: Bear Market
Want to see what other hedge funds are holding MDSO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medidata Solutions Inc (NASDAQ:MDSO).
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.